The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice


如何引用文章

全文:

详细

The treatment of patients with ovarian cancer remained unchanged over the past years: cytoreductive surgery and platinum-based chemotherapy regardless of the histological type of the tumor. A deeper understanding of ovarian cancer biology has paved the way to developing targeted drugs; the most studied are bevacizumab and olaparib (Lynparza) - the first among PARP inhibitors, which has been recently approved in the world and in Russia. Olaparib demonstrated a statistically significant efficacy in the treatment using supportive regimen in patients with recurrent platinum-sensitive ovarian cancer after successful platinum-based chemotherapy and with the presence of BRCA1/2 mutations and all these characteristics would significantly change the course of the disease in this group of patients.

作者简介

S Khokhlova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: svkhokhlova@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Cancer Research UK. Cancer mortality for common cancers. 2011. http://www.cancerresearchuk.org
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
  3. Raja F.A, Chopra N, Ledermann J.A. Optimal first - line treatment in ovarian cancer. Ann Oncol 2012; 23 (Suppl. 10): x118-27.
  4. European Medicines Agency. Lynparza. International non - pro - prietary name: Olaparib. European public assessment report. 014. http://www.ema.europa.eu
  5. Ledermann J.A, Raja F.A, Fotopoulou C et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2013; 24 (Suppl. 6): vi24-32.
  6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
  7. Wiedemeyer W.R, Beach J.A, Karlan B.Y. Reversing platinum resistance in high - grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 2014; 4: 34. doi: 10.3389/fonc.2014.00034
  8. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum - sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15 (8): 852-61.
  9. Khalique S, Hook J.M, Ledermann J.A. Maintenance therapy in ovarian cancer. Curr Opin Oncol 2014; 26 (5): 521-8.
  10. Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013; 5 (2): 133-41.
  11. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 2013; 288 (2): 367-74.
  12. Shaw H.M, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013; 6: 1197-206.
  13. Lheureux S, Oza A.M. Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs 2014; 2 (5): 497-508.
  14. Basu B, Sandhu S.K, de Bono J.S. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012; 72 (12): 1579-90.
  15. De Lorenzo S.B, Patel A.G, Hurley R.M et al. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013; 3: 228. doi: 10.3389/fonc.2013.00228.
  16. Lee J.M, Ledermann J.A, Kohn E.C. PARP inhibitors for BRCA1/2 mutation - associated and BRCA-like malignancies. Ann Oncol 2014; 25 (1): 32-40.
  17. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double - strand break repair. J Clin Oncol 2008; 26 (22): 3785-90.
  18. Lord C.J, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013; 19: 1381-8.
  19. Press J.Z, de Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17. doi: 10.1186/1471-2407-8-17.
  20. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation - positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-63.
  21. Beristain E, Martínez-Bouzas C, Guerra I et al. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counseling. Breast Cancer Res Treatment 2007; 106 (2): 255-62.
  22. Frank T.S, Deffenbaugh A.M, Reid J.E et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20 (6): 1480-90.
  23. Konecny M, Milly M, Zavodna K et al. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Breast Cancer Res Treatment 2011; 126 (1): 119-30.
  24. Marroni F, Aretini P, D’Andre E et al. Penetrances of breast and ovarian cancer in a large series of families tested BRCA1/2 mutations. Eur J Hum Genet 2004; 12 (11): 899-906.
  25. Nanda R, Schumm L.P, Cummings S et al. Genetictestingin an ethnically diverse cohort of high - risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. J Am Med Assoc 2005; 294 (15): 1925-33.
  26. Seymour I.J, Casadei S, Zampiga V et al. Results of a population - based screening for hereditary breast cancer in a region of North - Central Italy: contribution of BRCA1/2 germ - line mutations. Breast Cancer Res Treatment 2008; 112 (2): 343-9.
  27. Weitzel J.N, Lagos V, Blazer K.R et al. Prevalence of BRCA mutations and founder effect in high - risk Hispanic families. Cancer Epidemiol, Biomarkers Prevent 2005; 14 (7): 1666-71.
  28. Gayther S.A, Russell P, Harrington P et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer - susceptibility genes. Am J Hum Genet 1999; 65 (4): 1021-9.
  29. Anton-Culver H, Cohen P.P, Gildea M.E, Ziogas A. Characteristics of BRCA1 mutations in a population - based case series of breast and ovarian cancer. Eur J Cancer 2000; 36 (10): 1200-8.
  30. Janezic S.A, Ziogas A, Krumroy L.M et al. Germline BRCA1 alterations in a population - based series of ovarian cancer cases. Hum Molecular Genet 1999; 8 (5): 889-97.
  31. Risch H.A, Mc Laughlin J.R, Cole D.E.C et al. Population BRCA1 and BRCA2 mutation frequencies and cancer pene - trances: a kin - cohort study in Ontario, Canada. J Nat Cancer Institute 2006; 98 (23): 1694-706.
  32. Stratton J.F, Gayther S.A, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. New Engl J Med 1997; 336 (16): 1125-30.
  33. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation - positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012; 30 (21): 2654-63.
  34. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121 (2): 353-7.
  35. Stavropoulou A.V, Fostira F, Pertesi M et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS ONE 2013; 8 (3).
  36. De Leeneer K, Coene I, Crombez B et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treatment 2012; 132 (1): 87-95.
  37. Brozek I, Ochman K, Debniak J et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108 (2): 433-7.
  38. Smirnova T.Y, Pospekhova N.I, Lyubchenko L.N et al. High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer. Bul Experimental Biol Med 2007; 144 (1): 83-5.
  39. Lim M.C, Kang S, Seo S et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol 2009; 135 (11): 1593-9.
  40. Boyd J, Sonoda Y, Federici M.G et al. Clinicopatholic features of BRCA-linked and sporadic ovarian cancer. J Am Medl Assoc 2000; 283 (17): 2260-5.
  41. Berchuck A, Heron K, Carney M.E et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4 (10): 2433-7.
  42. Lakhani S.R, Manek S, Penault-Llorca F et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10 (7): 2473-81.
  43. Rubin S.C, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. New Engl J Med 1996; 335 (19): 1413-6.
  44. Shaw P.A, Mc Laughlin J.R, Zweemer R.P et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21 (4): 407-11.
  45. Werness B.A, Ramus S.J, Whittemore A.S et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31 (11): 1420-4.
  46. Mavaddat N, Barrowdale D, Andrulis I.L et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prevention 2012; 21 (1): 134-47.
  47. Safra T, Borgato L, Nicoletto M.O et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 2011; 10: 2000-7.
  48. Adams S.F, Marsh E.B, Elmasri W et al. A high response liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 123: 486-91.
  49. Kaye S.B, Lubinski J, Matulonis U et al. Phase II, open - label, randomized, multicenter study comparing the effıcacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-9.
  50. Tewey K.M, Rowe T.C, Yang L et al. Adriamycin - induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
  51. Hyman D.M, Zhou Q, Arnold A.G et al. Topotecan in patients with BRCA-associated and sporadic platinum - resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2011; 123: 196-9.
  52. Safra T, Rogowski O, Muggia F.M. The effect of germ - line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 2014; 24: 488-95.
  53. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205-14.
  54. Thorn C.F, Oshiro C, Marsh S et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440-6.
  55. David S.P, Tan D.S, Kaye S.B. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? ASCO EDUCATIONAL BOOK 2015; p. 114-2.
  56. Baird R.D, Tan D.S, Kaye S.B. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010; 7: 575-82.
  57. Quinn J.E, Carser J.E, James C.R et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113: 134-42.
  58. Chabalier C, Lamare C, Racca C et al. BRCA1 down regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006; 5: 1001-7.
  59. Tan D.S, Yap T.A, Hutka M et al. Implications of BRCA1 and BRCA2 mutations for the effıcacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 2013; 49: 1246-53.
  60. Tassone P, Tagliaferri P, Perricelli A et al. BRCA expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88: 1285-91.
  61. Zhou C, Smith J.L, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22: 2396-404.
  62. Fong P.C, Boss D.S, Yap T.A et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361 (2): 123-34.
  63. Fong P.C, Yap T.A, Boss D.S et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum - free interval. J Clin Oncol 2010; 28 (15): 2512-9.
  64. Audeh M.W, Carmichael J, Penson R.T et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof - of - concept trial. Lancet 2010; 376 (9737): 245-51.
  65. Kaufman B, Shapira-Frommer R, Schmutzler R.K et al. Olaparib monotherapy in patients. Curr Oncol Rep (2016) 18:29 with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33 (3): 244-50.
  66. Domchek S.M, Aghajanian C, Shapira-Frommer R et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016; 140 (2): 199-203.
  67. Lee J.M, Hays J.L, Annunziata C.M et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation - associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106 (6): dju089. Pubmed Central PMCID: 4049120.
  68. Oza A.M, Cibula D, Benzaquen A.O et al. Olaparib combined with chemotherapy for recurrent platinum - sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16 (1): 87-97.
  69. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum - sensitive re - lapsed ovarian cancer. N Engl J Med 2012; 366 (15): 1382-92.
  70. Jonathan A Ledermann, Philipp Harter. Overall survival in patients with platinum - sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo - controlled, double - blind, phase 2 trial. Lancet Oncol 2016; 17: 1579-89.
  71. Jonathan A Ledermann, Philipp Harter et al. Quality of life during olaparib maintenance therapy in platinum - sensitive relapsed serous ovarian cancer. Br J Cancer 2016; 1-8. doi: 10.1038/bjc. 2016.348.
  72. Kathleen N Moore, Bradley J Monk. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016; 21: 1-10.
  73. Michael Friedlander, Susana Banerjee. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum - sensitive recurrent ovarian cancer. Asia - Pacific J Clin Oncol 2016; 12: 323-31.
  74. Jonathan A Ledermann, Sessa C et al. eUpdate - Ovarian cancer treatment recommendations. ESMO 2016.
  75. Тюляндин С.А., Деньгина Н.В., Коломиец Л.А. и др. Практические рекомендации по лекарственному лечению рака яичников/первичного рака брюшины/рака маточных труб. Злокачественные опухоли. 2016; 4 (Спецвып. 2): 123-34.

版权所有 © Consilium Medicum, 2016

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##